"Angiogenesis"; axitinib is approved for renal cell carcinoma, bevacizumab is approved for metastatic colon, lung, renal, ovarian, GBM, and sunitinib for renal cell carcinoma, GIST and target is VEGF. This evidence concerns the gene VEGFA and hereditary clear cell renal cell carcinoma.